Building a quality-of-life questionnaire for people with metastatic breast cancer
Develops a questionnaire on quality of life in women with metastatic breast cancer.
Plain-language title generated from the registry record
Registry title: EORTC Metastatic Breast Cancer Module Development
Key facts
- Where
- Montreal and Toronto, CanadaSee the 2 sites
Where in Canada
- Centre Hospitalier de l'Université de MontréalMontreal, CanadaNot yet recruiting
- Odette Cancer Center - Sunnybrook Health Sciences CenterToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Leeds
- Trial code
- NCT07806266
- Record updated
- 8 September 2026
- Original description
The overall aim of this project is to help improve the Health Related Quality of Life (HRQOL) of metastatic breast cancer (MBC) patients. There is currently an urgent and unmet need for specific tools to aid in the evaluation of HRQOL in MBC and this project aims to address these needs by developing a comprehensive EORTC questionnaire for assessing the HRQOL of this group. The new module will be used in conjunction with EORTC QLQ-C30 and will provide better measurement of the quality of life issues experienced by women with MBC. Interviews will be conducted with patients from several centres across Europe, guiding the development process in a patient centred way.Read full original descriptionShow less
The European Organisation for Research and Treatment of Cancer: Module Development for Metastatic Breast Cancer (Phase I-IIIa/b)
The overall aim of this project is to help improve the Health Related Quality of Life (HRQOL) of metastatic breast cancer (MBC) patients. There is currently an urgent and unmet need for specific tools to aid in the evaluation of HRQOL in MBC and this project aims to address these needs by developing a comprehensive EORTC questionnaire for assessing the HRQOL of this group. The new module will be used in conjunction with EORTC QLQ-C30 and will provide better measurement of the quality of life issues experienced by women with MBC. Interviews will be conducted with patients from several centres across Europe, guiding the development process in a patient centred way.
Inclusion: Adult females aged 18 years or over; Have a diagnosis of MBC (Breast cancer that has spread to another part of the body), including de novo MBC patients. Patients with brain metastases will be included, providing there is no associated major cognitive impairment; Have received (patients under observation) or currently receiving treatment for MBC, including chemotherapy, hormone therapy, targeted agents (anti-HER2, CDK4/6 inhibitors, mTOR/PIK3CA inhibitors, PARP inhibitors, immune therapy), radiotherapy and combinations; Conversant in the language of questionnaire administration; Have the capacity to give informed consent.
Exclusion: Patients previously involved in Phase I; Patients diagnosed with early stage breast cancer; Patients with any psychiatric condition or cognitive impairment, as determined by the treating physician, that would hamper participation in interviews.